1999 Volume 45 Issue 3 Pages 245-250
Currently the retained extract from Japanese cedar pollen (JCP), a product manufactured by Torii Pharmaceutical Co., Ltd., is widely used in Japan for the treatment of patients allergic to JCP. However, it is not standardized, yet. Recently a new standardized allergen extract from JCP (TO-194) has been produced. The purpose of this study is to compare the allergenic potency of each extract. The potency was assayed by the intradermal titration technique; each extract in 3-fold serial dilutions was injected simultaneously in 50 patients with Japanese cedar pollinosis, and the threshold values for positive reactions were employed for the analysis in 44 patients. As a result, TO -194 was found to be more potent than the currently retained extract. In addition, no adverse side effects were seen in either group (48 patients in all were analized) on the first day and the next three days. Based on the above findings, TO -194 is thus considered to be preferable to the currently retained extract for immunotherapy in patients allergic to JCP.
